{"created":"2023-06-19T07:26:03.759106+00:00","id":14305,"links":{},"metadata":{"_buckets":{"deposit":"65af1fe0-8bfa-4db8-86ef-95cadb59b206"},"_deposit":{"created_by":124,"id":"14305","owners":[124],"pid":{"revision_id":0,"type":"depid","value":"14305"},"status":"published"},"_oai":{"id":"oai:gifu-pu.repo.nii.ac.jp:00014305","sets":["212:260:312"]},"author_link":["33171","33172","33169","33167","33170","33168"],"item_3_biblio_info_3":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"104","bibliographicPageStart":"99","bibliographicVolumeNumber":"40","bibliographic_titles":[{"bibliographic_title":"CHROMATOGRAPHY"},{"bibliographic_title":"CHROMATOGRAPHY","bibliographic_titleLang":"en"}]}]},"item_3_textarea_2":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_textarea_value":"To construct liquid chromatography (LC)-based bioanalytical method for therapeutic monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), twelve commercially available therapeutic mAbs and one ADC were chemically reduced, and the generated fragments were analyzed by high-temperature reversed-phase LC. For most therapeutic mAbs, single peaks of light and heavy chains were detected, indicating a possibility of homogeneous LC analysis using light chains. However, characteristic fragmentations were observed in infliximab, pembrolizumab, ramucirumab, and trastuzumab emtansine. We also performed a simple validation using the fragmented light chains for the bioanalysis of bevacizumab. The limit of detection (LOD) and limit of quantification (LOQ) of bevacizumab were 0.63 and 2.10 µg/mL, respectively, with dithiothreitol reduction, and 0.74 and 2.48 µg/mL, respectively, with tris (2-carboxyethyl) phosphine reduction. These results indicate that both the reductants confer sufficient linearity, LOQ, and LOD for the light chain analysis of bevacizumab. Thus, this method, combined with affinity purification, can be used for the bioanalysis of bevacizumab."}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"High-temperature reversed-phase LC","subitem_subject_scheme":"Other"},{"subitem_subject":"Therapeutic monoclonal antibody","subitem_subject_scheme":"Other"},{"subitem_subject":"Antibody-drug conjugate","subitem_subject_scheme":"Other"},{"subitem_subject":"Chemical reduction","subitem_subject_scheme":"Other"},{"subitem_subject":"Bioanalysis","subitem_subject_scheme":"Other"},{"subitem_subject":"High-temperature reversed-phase LC","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Therapeutic monoclonal antibody","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Antibody-drug conjugate","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Chemical reduction","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Bioanalysis","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"High-Temperature Reversed-Phase LC Separation of Heavy and Light Chain Fragments of Therapeutic Monoclonal Antibodies and Antibody-Drug Conjugate Produced by Chemical Reduction","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"High-Temperature Reversed-Phase LC Separation of Heavy and Light Chain Fragments of Therapeutic Monoclonal Antibodies and Antibody-Drug Conjugate Produced by Chemical Reduction"},{"subitem_title":"High-Temperature Reversed-Phase LC Separation of Heavy and Light Chain Fragments of Therapeutic Monoclonal Antibodies and Antibody-Drug Conjugate Produced by Chemical Reduction","subitem_title_language":"en"}]},"item_type_id":"3","owner":"124","path":["312"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-03-08"},"publish_date":"2021-03-08","publish_status":"0","recid":"14305","relation_version_is_last":true,"title":["High-Temperature Reversed-Phase LC Separation of Heavy and Light Chain Fragments of Therapeutic Monoclonal Antibodies and Antibody-Drug Conjugate Produced by Chemical Reduction"],"weko_creator_id":"124","weko_shared_id":-1},"updated":"2023-06-19T07:44:09.556892+00:00"}